How Pharma Can Adjust to Global Market Uncertainty

In the final part of Pharmaceutical Commerce’s conversation with Jessica Lovett, VP of commercial strategy and innovation at Innomar Strategies, live from Asembia AXS26, the discussion focuses on how manufacturers and partners are adapting market access and commercialization strategies amid global political, regulatory, and reimbursement uncertainty.

Lovett describes uncertainty as “a matter of discipline,” pointing to the increasing complexity of navigating differences across global markets, including tax considerations, payer decisions, patient support funding structures, and product administration requirements. Using Canada as an example, she explains that specialty pharmaceuticals and biologics may be supported, regulated, and reimbursed very differently than in the US or Europe, making a “global lift and shift” approach less viable. She also notes that factors such as whether a therapy is infused, injectable, or oral can further complicate patient access planning and infrastructure needs.

To adapt, Lovett emphasizes the importance of being connected to the broader access ecosystem and leveraging partnerships that can provide both global insight and local market intelligence. She says organizations must increasingly evaluate market-specific regulatory, payer, and operational considerations in advance, while also maintaining the flexibility to pivot quickly as global and local market conditions continue to evolve.

Watch the first and second parts of Lovett’s interview with PC:

1. Asembia AXS26: Jessica Lovett on the RWE That Matters Most
2. How Specialty Drug Commercialization Differs in Canada from the US